Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

In patients with PD-L1 expression of more than 5%, OS improved further to 16.4 months versus 12.8 months. Tevimbra targets the PD-1 receptor, a checkpoint protein that suppresses the immune response.

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability as models for PD-1 studies.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past ...

Human, mouse PD-1 differ inside and out The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between ...

Phylloceuticals has produced its first plant-based PD-1 inhibitor monoclonal antibody only 12 weeks after launching operations in Rapid City, SD.

RM-0256 targets Programmed Cell Death Ligand 1 (PD-L1), a key immune checkpoint protein that allows tumors to evade immune detection by binding to PD-1 receptors on activated T cells.

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).